M&A Deal Summary

COI Pharmaceuticals Acquires Calporta Therapeutics

On November 13, 2019, COI Pharmaceuticals acquired life science company Calporta Therapeutics for 576M USD

Acquisition Highlights
  • This is COI Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is COI Pharmaceuticals’ largest (disclosed) transaction.
  • This is COI Pharmaceuticals’ 1st transaction in the United States.
  • This is COI Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2019-11-13
Target Calporta Therapeutics
Sector Life Science
Buyer(s) COI Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 576M USD

Target

Calporta Therapeutics

La Jolla, California, United States
Calporta Therapeutics, Inc. develops selective small molecule agonists to TRPML1. TRPML1 is believed to play a role in lysosomal function by promoting autophagy and lysosomal exocytosis. Calporta’s preclinical stage TRPML1 agonists are being evaluated for their potential to treat various lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

COI Pharmaceuticals

San Diego, California, United States
Category Company
Founded 2013
Sector Business Services
DESCRIPTION

COI Pharmaceuticals is a life science incubator entity that provides inventors with an environment where entrepreneurial and scientific risks are encouraged and rewarded. COI provides the intellectual capital to launch companies, a fully-equipped R&D infrastructure and industry mentors prepared to leverage their expertise to help entrepreneurial scientists succeed.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-11 Sitari Pharmaceuticals

San Diego, California, United States

Sitari Pharmaceuticals was targeting the Transglutaminase 2 (TG2) pathway for the development of treatments for celiac disease. TG2 is thought to play a multi-factorial role in celiac disease. TG2 is the primary human protein that is attacked as part of an autoimmune response in patients with celiac disease. The enzyme is also responsible for catalyzing a reaction with dietary gluten peptides that drives the pathogenesis of the disease, according to company data. Sitari had been developing targeted inhibitors of TG2 with the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients.

Sell -
Mergr

Product

Company

Legal